ArticleJournal of clinical medicine2025

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Giammarco Mocci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.